Michael A. Metzger
CEO & DirectorMr. Michael A. Metzger is an Independent Director at Pyxis Oncology, Inc since June 10, 2024. Mr. Metzger has experience in the biopharmaceutical sector, is serving as Chief Executive Officer since February 2022 and as a member of the Board of Directors of Syndax Pharmaceuticals, Inc. since 2015.and previously served as its President and Chief Operating Officer from May 2015 Before joining Syndax, Mr. Metzger was President and COO from December 2013 to October 2014 and President, Chief Executive Officer and a member of the board of directors of Regado Biosciences, Inc. leading to its merger with Tobira Therapeutics and sale to Allergan, COO of Mersana Therapeutics and senior business development roles at Forest Laboratories.Metzger served as Vice President Corporate Development at Onconova Therapeutics, Inc. and was a Managing Director at MESA Partners, Inc., He most recently served on the board of CTI Biopharma Corp., a publicly traded biopharmaceutical company which was acquired by SOBI AB in 2023. Mr. Metzger received a B.A. from George Washington University and an M.B.A. in finance from the New York University Stern School of Business.
Positions
- Company NameSyndax Pharmaceuticals, Inc.Stock CodeSNDXPositionCEO & DirectorColleagues
- DGDennis G. PodlesakIndependent Chairman
- LJLuke J. AlbrechtGeneral Counsel & Corporate Secretary
- KAKeith Alan GoldanExecutive Officer
- SCSteven ClosterChief Commercial Officer
- NANicholas A.J. BotwoodHead of Research & Development and Chief Medical Officer
- PLPierre LegaultIndependent Director
- KAKeith A. KatkinIndependent Director
- JAJennifer A. JarrettIndependent Director
